Ustekinumab-aekn (Selarsdi) has been approved as interchangeable with the reference biologic ustekinumab (Stelara) for various indications, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, in both adult and pediatric patients. This approval is part of a strategic partnership between Alvotech and Teva Pharmaceuticals, aiming to expand access to biosimilars. The safety profile of the ustekinumab biosimilar is consistent with the reference product, with risks for serious infections and other adverse events.

Source: Teva Pharmaceuticals